Zelira Therapeutics (ASX:ZLD) has announced the successful enrolment of 60 patients in the clinical trial of its cannabinoid medicine for diabetic nerve pain.
The trial will evaluate the efficacy, safety and tolerability of its proprietary, patent-protected product.
The trial was designed and approved as an observational multi-arm, head-to-head study. The company said it expects to provide a trial readout in the first quarter of 2023.
Zelira Therapeutics CEO and managing director Dr Oludare Odumosu said, “Our company is pleased with the successful completion of enrolment of this IRB-approved trial, conducted in the United States and look forward to the analyses and readout of the study results.
“This unique, multi-arm comparative study presents multiple prospects for positive readouts on study endpoints. A positive result on one or more endpoints would be a landmark event for our company and in line with our value-creation strategy of generating scientifically rigorous, clinically validated data for our patent-protected, proprietary cannabinoid-based drugs.
“Above all, positive results will validate the real potential for creating safer and efficacious cannabinoid medicines for the treatment of diabetic nerve pain.”